UB Paderborn / Katalog / Suche / in CDI

1 – 18 von 18

Sortiert nach

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis

American journal of hematology, 2005-08, Vol.79 (4), p.319-328

2005

Link zum Volltext

Verfügbarkeit prüfen

Responses to salvage therapy in AL amyloidosis after progression on daratumumab

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e20030-e20030

2022

Link zum Volltext

Verfügbarkeit prüfen

Combined use of two monoclonal antibodies in patients with systemic AL amyloidosis and cardiac involvement

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.8009-8009

2019

Link zum Volltext

Verfügbarkeit prüfen

Seeking light-chain amyloidosis very early: The SAVE trial—identifying clonal lambda light chain genes in patients with MGUS or smoldering multiple myeloma

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.8010-8010

2019

Link zum Volltext

Verfügbarkeit prüfen

Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.8546-8546

2020

Link zum Volltext

Verfügbarkeit prüfen

Patient Experience With Light Chain Amyloidosis: A Survey From the Amyloidosis Research Consortium

Journal of cardiac failure, 2015-08, Vol.21 (8), p.S63-S63

2015

Link zum Volltext

Verfügbarkeit prüfen

Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.8011-8011

2018

Link zum Volltext

Verfügbarkeit prüfen

Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8514-8514

2015

Link zum Volltext

Verfügbarkeit prüfen

Pre-clinical translational studies of daratumumab in patients with myeloma or AL amyloidosis undergoing autologous hematopoietic stem cell transplantation (SCT)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8587-8587

2015

Link zum Volltext

Verfügbarkeit prüfen

The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.8614-8614

2015

Link zum Volltext

Verfügbarkeit prüfen

NEOD001 Demonstrates Cardiac and Renal Biomarker Responses in a Phase 1/2 Study in Patients With AL Amyloidosis and Persistent Organ Dysfunction

Journal of cardiac failure, 2015-08, Vol.21 (8), p.S15-S15

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy

Clinical lymphoma, myeloma and leukemia, 2017-02, Vol.17 (1), p.e14-e15

2017

Link zum Volltext

Verfügbarkeit prüfen

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004

American journal of hematology, 2005-08, Vol.79 (4), p.319-328

2005

Link zum Volltext

Verfügbarkeit prüfen

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

Leukemia, 2009-09, Vol.23 (9), p.1545-1556

2009

Link zum Volltext

Verfügbarkeit prüfen

Trisomy 13q in a case of acute leukemia with lineage inconsistency

Cancer genetics and cytogenetics, 1991-08, Vol.55 (1), p.107-111

1991

Link zum Volltext

Verfügbarkeit prüfen

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

Leukemia, 2009-02, Vol.23 (2), p.215-224

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 18 von 18

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(17)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(18)

Sprache

Englisch
(18)
Japanisch
(4)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Journal Of Clinical Oncology
(8)
Leukemia
(4)
American Journal Of Hematology
(2)
Journal Of Cardiac Failure
(2)
Cancer Genetics And Cytogenetics
(1)
Clinical Lymphoma, Myeloma And Leukemia
(1)

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis

Responses to salvage therapy in AL amyloidosis after progression on daratumumab

Combined use of two monoclonal antibodies in patients with systemic AL amyloidosis and cardiac involvement

Seeking light-chain amyloidosis very early: The SAVE trial—identifying clonal lambda light chain genes in patients with MGUS or smoldering multiple myeloma

Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial

Patient Experience With Light Chain Amyloidosis: A Survey From the Amyloidosis Research Consortium

Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda

Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction

Pre-clinical translational studies of daratumumab in patients with myeloma or AL amyloidosis undergoing autologous hematopoietic stem cell transplantation (SCT)

The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction

NEOD001 Demonstrates Cardiac and Renal Biomarker Responses in a Phase 1/2 Study in Patients With AL Amyloidosis and Persistent Organ Dysfunction

Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

Trisomy 13q in a case of acute leukemia with lineage inconsistency

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

Suchergebnisse filtern